Artificial Intelligence and Hepatocellular Carcinoma
Launched by HUMANITAS CLINICAL AND RESEARCH CENTER · Dec 1, 2022
Trial Information
Current as of January 22, 2025
Active, not recruiting
Keywords
ClinConnect Summary
Hepatocellular carcinoma (HCC) is 1 of the 5 most common malignancies worldwide and the third most common cause of cancer related mortality of 500,000 deaths globally every year.
Although more common in East Asia, the incidence of HCC is increasing in the Western world. Hepatic resection is the first-line therapeutic option, and it is accepted as a safe treatment with a proven impact on prognosis, with a low operative mortality as the result of advances in surgical techniques and perioperative management. Nevertheless, surgical resection is applicable in only about 20% to 30% of patients w...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>= 18 years old.
- • Hepatocarcinoma diagnosis confirmed at histological specimen
- • Being at the first HCC diagnosis or with a recurrence/persistence disease evaluated and treated for the first time with surgery at the participating center.
- • Available contrast-enhanced CT Scan obtained no more than 1 month prior to surgery.
- Exclusion Criteria:
- • Surgery as a downstaging therapy for transplant
- • Patients treated with surgery in case of not-curative intent (palliation, best supportive care, etc).
- • Histopathological specimen of combined liver primary neoplasms (e.g. 'epatocolangiocarcinoma').
About Humanitas Clinical And Research Center
Humanitas Clinical and Research Center is a leading institution dedicated to advancing healthcare through innovative clinical research and patient-centered care. Located in Italy, the center specializes in conducting high-quality clinical trials across various therapeutic areas, including oncology, cardiology, and neurology. With a commitment to scientific excellence and ethical standards, Humanitas collaborates with academic institutions, pharmaceutical companies, and healthcare organizations to foster groundbreaking discoveries and improve patient outcomes. The center's multidisciplinary team of experts leverages state-of-the-art facilities and cutting-edge technologies to ensure rigorous study design and execution, ultimately contributing to the advancement of medical knowledge and the development of new therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rozzano, Lombardy, Italy
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials